ARK Innovation ETF's 12.5% annual total return since inception only slightly lags the S&P 500, but with its high volatility, ARKK's Sharpe Ratio is significantly worse. The ETF's top 10 holdings ...
Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Scorpion Therapeutics, Vividion Therapeutics, Fore Biotherapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback